UPDATE: Jefferies & Company Terminates Coverage on Biosante Pharmaceuticals
In a report published Friday, Jefferies & Company terminated its coverage on Biosante Pharmaceuticals (NASDAQ: BPAX).
Jefferies noted, “Due to a reallocation of resources, we are dropping coverage of BioSante Pharmaceuticals (BPAX). Our last rating on BioSante was Hold with a $2 price target...Our $2 PT was based on a DCF taken out to 2026, discounted at 20%. Our most recent published risks included the potential for additional dilutive financings and pipeline setbacks.”
Biosante Pharmaceuticals closed on Friday at $1.30.
Latest Ratings for BPAX
|Oct 2012||Jefferies & Company||Drops Coverage on|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.